|« Previous||Main||Next »|
I have written before about the deplorable NHS policy of restricting access to life-saving medications. Anyone doubting that the “reformers” who now control D.C. have the same thing in mind for us should read this WSJ piece:
In Britain, a government agency evaluates new medical products for their “cost effectiveness” before citizens can get access to them … Here in the U.S., President-elect Barack Obama and House Democrats embrace the creation of a similar “comparative effectiveness” entity.
What do they mean by “cost effectiveness” and “comparative effectiveness”? They mean that dying patients will not be allowed access to certain drugs if they ”cost too much.”
In Britain, a government agency evaluates new medical products for their “cost effectiveness” before citizens can get access to them. The agency has concluded that $45,000 is the most worth paying for products that extend a person’s life by one “quality-adjusted” year.
In other words, they decide how much your life is worth and withhold any treatment whose cost exceeds that arbitrary amount. The worst feature of this grotesque and deadly policy is that it won’t save any money:
The Congressional Budget Office says that government-run comparative effectiveness studies won’t actually save much money.
Even more ironic, this policy will be implemented at a time when the federal government is involved in a wild orgy of spending. I wonder how many of the people who hailed O’s inauguration yesterday have any idea what sort of “change” they’re in for.
+ May 2008
+ May 2007